anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Prompt institution of appropriate regimens for care of the burned patient is of prime importance and includes the control of shock and pain. The burn wounds are then cleansed and debrided; Thermazene Cream is then applied under sterile conditions. The burn areas should be covered with Thermazene Cream at all times. The cream should be applied once to twice daily to a thickness of approximately one sixteenth of an inch. Whenever necessary, the cream should be reapplied to any areas from which it has been removed due to patient activity. Administration may be accomplished in minimal time because dressings are not required. However, if individual patient requirements make dressings necessary, they may be used. 

Reapply immediately after hydrotherapy. Treatment with Thermazene Cream should be continued until satisfactory healing has occurred or until the burn site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection except if a significant adverse reaction occurs.
The invention relates to a Zhizhongtang integrated novel dosage form and a production method of the novel dosage form. The raw material composition in part by weight of the effective components of the novel dosage form is as follows: 5 parts of Panax ginseng, 5 parts of Glycyrriza uralensis, 5 parts of dried Zingiber officinale, 5 parts of Atractylodes macrocephala, 5 parts of Citrus reticulata and 2 parts of Citrus reticulata. The production process comprises the steps of supersonic jet milling, alcohol water extraction, ultrasonic pulverization extraction, water decoction and concentration, supersonic spray drying, nano grinding, high pressure homogenization, nano particles preparation and the like. The invention pays attention to the advantages of multi-coordination, multi-target and the like showed by utilizing nano carrier combined technique, after large-scale production, the production cost can be greatly reduced, the product quality is greatly improved, and the targeting and sustained or controlled release properties of the drugs are strong. The products made in the invention can be dosed in vivo and in vitro simultaneously, and can be taked at four periods of time respectively according to midnight-noon ebb-flow and human qi and blood circulation rules. The effective components of Zhizhongtang can also be prepared into a film-forming agent and a transdermal agent which is stick to different body parts according to midnight-noon ebb-flow and human qi and blood circulation rules for direct absorption through skin.
As Los Angeles County + University of Southern California Medical Center (LAC+USC) serves an indigent Latino population at increased risk for developing Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus (GDM) complicated 13% of deliveries at LAC+USC between 2006-2007. While over 50% of GDM patients will develop overt diabetes mellitus within a decade of the incident pregnancy, less than half of these patients ever return for even one post-partum follow up visit at this institution (45%). Lifestyle Interventions and medications have been shown to delay or prevent the onset of T2DM. However, prevention is only possible if patients follow-up and individual risk assessment is made. While identifying the 2-hour glucose tolerance test as the appropriate postpartum screening technique for patients with a history of GDM, the Fifth International Workshop-Conference on Gestational Diabetes Mellitus did not identify strategies to improve follow up among this patient population. Promotoras (bi-lingual, bi-cultural lay community health workers representative of the Latino community base) have been successful in improving follow up for other areas of diabetes and women's preventive services but have not been studies in the context of GDM. We will develop the Es Mejor Saber training materials and program and pilot a randomized control trial (RCT),a total 216 subjects completing a GDM affected pregnancy will be randomized on the postpartum ward to the standard-of-care versus proactive follow-up with a Promotora. The Promotora will provide education, address barriers to follow-up, remind subjects of their appointments, and call them to reschedule if they miss appointments. In the first phase of the study, these appointments will include the OGTT and the initial postpartum visit. In the second phase, these visits will include referrals to internal medicine (for those diagnosed with T2DM) or nutrition counseling (for those found not to have diabetes). The primary hypothesis underlying this proposal is that the introduction of a Promotora providing education and pro-active follow-up into postpartum GDM management will result improve post-partum follow-up for screening, treatment, and preventive services when compared with the standard of care.
PROBLEM TO BE SOLVED: To obtain a stabilized capsule, capable of preventing a sebum absorptivity of a polymer having the sebum absorptivity from deteriorating and good in touch especially as a cosmetic by coating a volatile liquid oily ingredient with the polymer and a specific ingredient. SOLUTION: This capsule having the sebum absorptivity is obtained by including a volatile liquid oily ingredient in a polymer ingredient having the sebum absorptivity and coating the periphery thereof with a solid oily ingredient. The temperature at which the solid oily ingredient starts melting is preferably 30-100 deg.C and higher than a temperature at which the volatile liquid oily ingredient starts solidifying. The weight ratio of the volatile liquid oily ingredient to the polymer ingredient is 0.5-10. The solid oily ingredient is higher fatty acids, animal or vegetable oils, hydrocarbons, esters, silicones, higher alcohols, coloring matters, etc. The volatile liquid oily ingredient is the higher fatty acids, animal or vegetable oils, hydrocarbons, esters, silicones, etc.  The resultant capsule is blended to afford the dermal preparation for external use having the sebum absorptivity. A suppressant for sebum secretion such as Aloe or Zizyphi Inermi Fructus is preferably blended in the dermal preparation for external use.
The present invention relates to a new antibody anti-nectin-4. Nectin-4 is a tumor-associated antigen overexpressed in several cancers and notably in 30%, 49% and 86% of breast, ovarian and lung carcinomas, respectively, which are tumors of bad prognosis. Treatments remain still elusive. That's why the inventors developed a new targeted therapy based on an antibody having specificity to nectin-4 (called 14A5.2 mab). Indeed, the inventors selected this antibody for its intrinsic prophylactic anti-metastatic properties and also for the treatment of localized primary and metastatic cancer. More, the 14A5.2 mab could be indicated for the treatment of cancer resistant to ASG-22ME (from Astellas company). Thus, the invention relates to the 14A5.2 mab and its uses thereof.
INTRODUCTION: Chronic subdural hematoma (cSDH), a condition that develops over time, is characterized by inflammation, angiogenesis, and membrane development. As the population's average age increases, the incidence of cSDH is expected to grow. While surgery is the primary treatment technique, medicinal therapy options are being explored for high-risk patients. Currently, the most effective therapy combination is dexamethasone (Dex) and atorvastatin (Ato); however, it is associated with an increased risk of mortality. This study explored the effects of bevacizumab (Bev), a vascular endothelial growth factor antagonist, on cSDH.
MATERIALS AND METHODS: Ninety-five rats were divided into four groups (n = 18): sham, control hematoma, Dex-Ato, and Bev. Two separate autologous blood injections into the subdural space were used as the model. Weight was monitored for all rats to assess changes in their overall health. The control group was given i.p. saline, the Dex-Ato treatment was given by gavage, and the Bev treatment was given i.p. On seventh, 14th and 21st days six rats from each group were sacrificed and analyzed, while 23 rats were excluded from the experiment.
RESULTS: The maximum immunological response to cSDH was observed on day 14. Hematoma volume decreased over time in all groups. Dex-Ato and Bev were both found effective, while Dex-Ato caused weight loss.
CONCLUSION: Bev had similar effects to the Dex-Ato group and was well tolerated by rats. Given that cSDH is a disease of the elderly and vulnerable populations, Bev may be a viable alternative that can shed light on the disease's etiology for future research.
Macrophages play vital roles in iron metabolism and are also modulated by iron. Macrophages are crucial to the recycling of iron and systemic iron homeostasis, and the functional heterogeneity of macrophages contributes to the different effects on iron metabolism. Conversely, iron can affect the development, function, and polarization of macrophages. Macrophages can initiate ferroptosis through a series of signaling pathways when overloaded with intracellular iron. Macrophages ferroptosis can aggravate local inflammatory reactions and promote the progression of various diseases such as metabolism, infection, and inflammation, so inhibiting macrophages ferroptosis may be an important therapeutic target. In addition, inhibiting M1-like macrophages ferroptosis and promoting M2-like macrophages ferroptosis are important in inhibiting the progression of malignant tumors.
INTRODUCTION: The current obesity crisis has resulted in many people with excess adipose tissue suffering from chronic inflammation. This inflammation is largely due to the release of cytokines and chemokines from visceral fat. The aim of this study was to identify potential anti-inflammatory agents that might alleviate obesity-induced chronic inflammation.
METHODS: To identify agents that might alleviate this obesity-induced chronic inflammation we have developed a simple protocol for incubating intact pieces of human visceral adipose tissue in 35 mm tissue culture plates, in the presence of low-dose lipopolysaccharide (LPS) and co-incubating these samples with potential anti-inflammatory agents. RNA-Seq analysis was performed to identify enriched gene expression signatures among the most significantly differentially expressed genes.
RESULTS: From this screen, we have identified the short-chain fatty acid (SCFA) sodium butyrate and its triacylglyceride form, tributyrin, as effective agents, significantly reducing the production of LPS-induced inflammatory cytokines and chemokines from all adipose tissue samples tested. As well, these agents appear to be non-toxic at the concentrations tested. RNA-Seq analysis has revealed that IL36γ is one of the most upregulated genes in response to LPS and one of the most downregulated when sodium butyrate is added to human fat samples stimulated with LPS. IL-36γ ELISAs confirmed this holds true at the protein level as well.
CONCLUSIONS: These studies suggest that the short-chain fatty acid, sodium butyrate, and its triacylglyceride form, tributyrin, might alleviate the chronic inflammation that is associated with many individuals with obesity.
PURPOSE: Insomnia and anorexia nervosa (AN) are frequently comorbid, negatively affecting the evolution and the prognosis of AN. Within this framework, the management of sleep disorders appears as critical. The aim of this retrospective study is to assess, for the first time, the efficacy of cognitive and behavioural therapy for insomnia (CBT-I) on sleep disturbances in adolescents with AN. To do so, we investigated the impact of CBT-I on sleep disturbances and sleep-related outcomes, in BMI, AN symptoms, anxiety and depressive symptoms, emotionality and quality of life. These features were compared between two groups of patients with AN, one following CBT-I, and the other receiving the regular treatment at the psychiatric unit.
METHODS: Data collection occurred between January and May 2022. The study included 42 adolescents in-treatment at the Eating Disorders care specialised unit at Salvator Hospital in Marseille. They were randomly assigned to the CBT-I group (N = 31) or the control group (N = 11). Several clinical elements were assessed using sleep diaries and self-report questionnaires.
RESULTS: Participants undergoing CBT-I showed a significant improvement in sleep latency, total wake time and sleep efficacy, as well as in physical well-being. No significant effects were found regarding AN symptoms.
CONCLUSION: These preliminary findings provide support for CBT-I effectiveness in adolescents with AN, as shown by significant improvements in several sleep parameters, as well as in physical well-being. These promising results, underline the relevance of this topic and its potential benefits for a more appropriate treatment for adolescents with AN.
LEVEL OF EVIDENCE: Level V, retrospective study.
ESWT was performed by the same physician. The applicator was placed at the point of maximum sensitivity. Two thousand pulses with a frequency of 6 Hz and a pressure of 3 bar were applied to patients with an Auto Wave 695 (Mettler electronics, USA) brand device. Patients underwent two sessions of ESWT per week for two weeks, adding up to a total of 4 sessions. Local or regional anesthesia was not administered to any patient during ESWT.
PURPOSE:To provide the titled promoting agent containing a specific unsaturated fatty acid or its ester as an active component. CONSTITUTION:The objective peripheral circulation promoting agent can be prepared by using a 8-24C unsaturated fatty acid having 1-3 C=C double bonds, or its ester (e.g. linoleic acide, linolenic acid, linolenic acid monoglyceride, etc.) as an active component, and adding an antioxidation agent (e.g. dl-alpha- tocopherol, nordihydroguaiaretic acid, extract of herb having antioxidation activity, etc.) to improve the effect of the unsaturated fatty acid. It is administered by oral administration, injection (intravenous, subcutaneous or intramuscular injection), external application, or in the form of suppository, etc., especially preferably by external application. Dose: preferably 0.1-1,000mg/kg daily for oral administration, and 0.01-1,000mg/kg daily for injection. In the case of external drug, a proper amount of a composition containing 0.01-10wt% active component is applied locally to the diseased part at a proper time.
PURPOSE:To improve the efficiency of diagnostic work and reduce labor in file management, by displaying medical picture by monitoring and, at the same time, editing corresponding indentification data, and diagnostic data are inputted through voice and edited in the same way, and then, displaying those edited data through a picture and voice after they are integrated and separated. CONSTITUTION:A medical picture collecting mechanism 14 A/D converts original pictures and store them once in a memory 7. These data are transferred to another memory 8 and displayed on a TV monitor 13 after picture processing. Doctors input their diagnostic views through a microphone 21. The name of patient, picture identification data and voice identification data are inputted through a CPU4. The diagnostic view and voice identification data are edited and written in a voice RAM19. A picture formatting circuit 10 edits the picture data and the identification data and writes them in a picture RAM11. An information integrating and separating section 3 integrates each data of the picture RAM11 and voice RAM19 and plants them in an FD23 or files them in an overall imaging center 25. The retrieval of those data is performed through the keyboard of the CPU4.
Bronchoscopy is a commonly performed procedure where a camera tipped device is used to look into a patient's lung. To perform bronchoscopy, a "standard commercial adapter" is connected to the ventilator tubing, which lets the doctors use the bronchoscope.The design of the "standard commercial adapter" can cause about 20% of air to escape from the ventilator to the OR. This leaked air causes two issues: first, this can lead to lower oxygen levels and can limit the amount of time your physician can perform bronchoscopy. Second, the leaked air can lead to the spread of harmful particles like anesthesia gas to the OR. These particles can harm the staff in the operating room or spread to other patients in the hospital.

This study will compare the benefit of the "standard commercial adapter" to the newly developed "leak-free adapter". The investigational procedure being studied here is repeating the bronchoscopy with the leak-free adapter. Outcomes (which measure the benefit of the new adapter) will be measured for each adapter independently. Bronchoscopy using both devices will be performed by the physician performing the procedure.
The present invention relates to a vortioxetine hydrobromide long-acting injection preparation. The preparation comprises vortioxetine hydrobromide, a suspending agent, a stabilizer, a buffering agent, a pH regulator, and a solvent. The preparation may be a ready-to-use liquid injection, and may also be a freeze-dried powder injection. After injection, the preparation has an obvious slow-release effect and can reduce times of administration, prolong the duration of the drug, improve patient compliance and increase bioavailability. Moreover, the present invention also provides a method for preparing the vortioxetine hydrobromide long-acting injection preparation. The method is simple and economic, and is applicable to industrial production.
<P>PROBLEM TO BE SOLVED: To provide a flow processing type micro-fluid device for improving the homogeneity of a mixture and a liquid mixture production apparatus having the device.  <P>SOLUTION: Each flow processing type micro-fluid device 109, 215 is designed such that many fine holes 613 and 624 are made in lines in a nozzle protective wall 621, thereby forming nozzle lines. The nozzle lines 602 and 603 are disposed parallel to each other. A lid member for defining each sheet-like mixing passage 601, 620 through which a solution led in from the nozzle lines is passed is defined on the back of the nozzle protective wall and between the nozzle protective wall and it. A second nozzle protective wall 610, which is open on one side such that a solution flowing from the fine holes is led downstream, is formed around a place corresponding to at least any one of the fine holes of the nozzle protective wall or lid member.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
1. A method for transdermal delivery of a pharmaceutically active agent to a subject, comprising: a) formulating said agent in a mixture of a mixture of principally mono unsaturated alcohols containing 14 to 24 carbon atoms, as represented by the formula CH3(CH2)mCH=CH(CH2)nCH2OH where m and n are 5 to 13 and the carbon-carbon double bonds are cis or trans, and b) applying such formulation topically to dermal areas of said subject. 2. The method of claim 1 wherein mixture of mono unsaturated alcohols is jojoba alcohol produced from jojoba oil. 3. The method of claim 1 wherein mixture of mono unsaturated alcohols is sperm alcohol produced from sperm whale oil. 4. The method of claim 1 wherein a long chain of mono unsaturated alcohols comprise a mixture the freezing point of which is 3 degree C and higher. 5. The method of claim 1 wherein a liquid chain of mono unsaturated alcohols is applied directly without any additional carrier for topical treatment of infections caused by herpes virus. 6. The of claim 5 wherein the virus is herpes simplex virus-1, also named herpes labialis, which causes facial irritations and sores. 7. The method of claim 5 wherein the virus is herpes simplex virus-2, also named herpes genitalis, which causes genital and anal area irritations and sores. 8. The of claim 5 wherein the virus is herpes simplex virus-3, also named herpes zoster and varicella zoster, which causes chicken pox and shingles. 9. The method of claim 5 wherein the virus is herpes simplex virus-8, which causes the skin cancer named Kaposi sarcoma. 10. The method of claim 1 further containing an antioxidant at 0.05 to 5 wt/vol.%. 11. The method of claim 10 wherein the antioxidant is tocopherol. 12. The method of claim 1 further containing a low molecular weight organic acid at 0.05 to 5 wt./vol.%. 13. The method of claim 12 wherein the low molecular weight organic acid is salicylic acid. 14. The method of claim 1 wherein the long chain mono unsaturated alcohol mixture contains both an antioxident and a low molecular weight organic acid. 15. The method of claim 1 wherein the active agent is ibuprofen for treating pains. 16. The method of claim 1 wherein the active agent is ketoprofen for treating pains. 17. The method of claim 1 wherein the active agent is dissolved in a mixture of principally mono unsaturated alcohols with ethyl alcohol or isopropyl alcohol to prepare a lotion for applying such formulation topically to dermal areas of said subject. 18. The method for the hydrogenolysis of a mixture of long chain esters comprising mono unsaturated alcohols and mono unsaturated carboxylic acid parts, using sodium bis-(2-methoxyethoxy)aluminum hydride as a metal hydride reducing agent.
INTRODUCTION: It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia.
MATERIALS AND METHODS: The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed.
RESULT: In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05).
CONCLUSIONS: In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.
The aerobic exercise will be developed in interval mode, on a treadmill with a negative slope of up to -6% for the intervention group, performing a 2-minute interval with the workload estimated in METS, followed by another 4-minute interval with half the work intensity. It will last between 20 and 30 minutes. The intensity or workload will be individualized (between low and medium), according to the functional status of each participant and will be gradually increased depending on their tolerance. The working heart rate will be between 60% and 80% of the theoretical maximum HR, the oxygen saturation. It should never go below 90% and the subjective perception of effort according to the modified Borg scale will have its objective between 4 and 6 maximum. The treadmill used is the Commercial X22i model from Nordictrack, with a maximum slope of -6º.
Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.